How changes in ribosomal RNA methylation affect cancer development
Mechanisms of aberrant ribosomal RNA (rRNA) methylation and altered mRNA translation in cancers
This study is looking at how changes in a specific part of our cells called ribosomal RNA might affect how cancer cells make proteins, with the hope of finding new ways to treat cancer that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10552554 on NIH RePORTER |
What this research studies
This research investigates how alterations in ribosomal RNA (rRNA) methylation can influence the translation of messenger RNA (mRNA) in cancer cells. By focusing on the oncogene Pelp1, the study aims to uncover the mechanisms that regulate rRNA methylation and how these changes contribute to tumor progression. The approach involves analyzing the effects of rRNA modifications on ribosome function and their role in producing proteins that promote cancer. Patients may benefit from insights that could lead to new therapeutic targets for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer or other malignancies where rRNA methylation may play a role.
Not a fit: Patients with non-cancerous conditions or those whose cancers do not involve rRNA methylation alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies targeting the mechanisms of rRNA methylation in cancer.
How similar studies have performed: Other research has shown promising results in targeting RNA modifications in cancer, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Denicourt, Catherine — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Denicourt, Catherine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.